Elevance Health revenue grows to $50.4 billion in Q3
- Elevance Health (NYSE:ELV) reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% year over year, with GAAP diluted earnings of $6.27 per share.
- Adjusted diluted EPS reached $6.99, exceeding market expectations, although results included a $1.85-per-share net non-operating benefit.
- Elevance increased its full-year adjusted EPS outlook to at least $29, GAAP EPS guidance to at least $22 and operating cash flow expectations to at least $6.5 billion.
Elevance Health (NYSE:ELV) reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% year over year, supported by its diversified healthcare businesses.
GAAP diluted earnings reached $6.27 per share, while adjusted diluted EPS totaled $6.99, with results benefiting from stronger operations and non-operating gains.
“Our third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business,” said CEO Gail Boudreaux.
The quarter included a $1.85-per-share net non-operating benefit, while improved medical cost performance helped strengthen profitability across the company's insurance operations.
Elevance raised its full-year GAAP diluted EPS guidance to at least $22 and adjusted EPS guidance to at least $29 from $27.
The company increased its 2026 operating cash flow forecast to at least $6.5 billion, compared with its previous expectation of at least $6 billion.
Elevance expects adjusted diluted EPS growth of at least 12% in 2027 from a baseline of at least $26.75, supported by Health Benefits and Carelon initiatives.
